Sacituzumab tirumotecan plus pembrolizumab versus pembrolizumab in PD-L1-positive advanced non-small-cell lung cancer (OptiTROP-Lung05): interim analysis of a randomised, open-label, phase 3 trial - P
an hour ago
- #immunotherapy combination
- #phase 3 trial
- #non-small-cell lung cancer
- Sacituzumab tirumotecan (sac-TMT) plus pembrolizumab vs pembrolizumab alone evaluated in PD-L1-positive advanced NSCLC in a phase 3 trial.
- Interim analysis showed significantly longer median progression-free survival with combination therapy (not reached vs 5.7 months; HR 0.35).
- Progression-free survival benefit consistent across PD-L1 subgroups: TPS 1-49% (HR 0.28) and TPS ≥50% (HR 0.47).
- Grade 3 or higher adverse events occurred in 55% of combination group vs 31% of pembrolizumab alone group.
- Trial suggests sac-TMT plus pembrolizumab could redefine first-line treatment for PD-L1-positive advanced NSCLC without targetable genomic alterations.